Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZLAB vs LEGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LEGN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–3 Matrix Metrics)

LEGN Overall Winner 6-Pillar Tally: ZLAB 1 – 4 LEGN (1 Tie) Matrix Metrics: ZLAB 3 – 7 LEGN

As of Nov 16, 2026, Legend Biotech Corporation (LEGN) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin), whereas LEGN carries 42.8/100 (HOLD) at $16.45 (27.5x Forward P/E, 2.8% operating margin).

  • Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. LEGN 42.8/100 HOLD), LEGN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.8% vs. -63.0% operating margin) and revenue trajectory (+32.0% vs. -6.8% YoY).
  • Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile LEGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZLAB vs LEGN
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.74
-3.5% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57
LEGN NASDAQ Head-to-Head Winner
Legend Biotech Corporation American Depositary Shares
Pharmaceutical Preparations
$16.45
-6.03% 1D
Market Cap $3.6B
TTM Revenue $1.36B
Forward P/E 27.5x
Beta / 30D Vol 0.65β · 82% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 27.0 Fund 45.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.0%), weak momentum, RSI 34
RSI-14: 34.5 · SMA20: $20.61 · SMA50: $19.47

6-Pillar Scorecard Institutional Category Breakdown (ZLAB 1 – 4 LEGN)

Columns: Metric · ZLAB · LEGN
1. Valuation Multiples LEGN
Forward P/E N/M 27.5x
Trailing P/E N/M 23.0x
PEG Ratio N/M N/M
EV / Revenue 6.8x 2.6x
2. Growth & Scale LEGN
Revenue Growth (YoY) -6.8% +32.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $442M $1.36B
Market Cap $3.0B $3.6B
3. Profitability & Quality LEGN
Gross Margin 0.6% 57.0%
Operating Margin -63.0% 2.8%
Net Profit Margin -44.9% -0.0%
Return on Equity (ROE) -30.0% -0.0%
4. Balance Sheet & Cash Flow LEGN
Cash Generation (TTM) -$262M EBITDA $50M EBITDA
Cash Flow Margin -59.3% EBITDA Mgn 3.7% EBITDA Mgn
Net Cash / Leverage $5.01 Book/Sh · -30.0% ROE $6.56 Book/Sh · -0.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 58.4% (58th %ile) 42.4% (24th %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ZLAB
OpEx & R&D Intensity 63.6% of Rev ($281M) 54.2% of Rev ($736M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZLAB (3) vs LEGN (7)
Institutional Metric ZLAB LEGN Criterion Row Edge
Market Capitalization
Scale
$3.0B $3.6B Larger Scale LEGN
Trailing P/E Ratio
Valuation
N/M 23.0x Lower Multiple LEGN
Forward P/E Ratio
Valuation
N/M 27.5x Lower Multiple LEGN
Revenue Growth (YoY)
Growth
-6.8% +32.0% Higher Growth LEGN
Operating Margin (TTM)
Profitability
-63.0% 2.8% Higher Margin LEGN
Net Profit Margin
Profitability
-44.9% -0.0% Higher Margin LEGN
Return on Equity (ROE)
Capital Efficiency
-30.0% -0.0% Higher ROE LEGN
52-Week Range Position
Momentum
60% ($16–$29) 1% ($16–$38) Stronger Trend ZLAB
Beta / 30D Volatility
Risk Regime
1.19β · 78% Vol 0.65β · 82% Vol Lower Realized Risk ZLAB
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 42.8 / 100 (HOLD) Higher Composite ZLAB
Trailing 12M Revenue (USD)
Operating Scale
$442M $1.36B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.6% 57.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · 2.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) $50M EBITDA ($6.56 Book/Sh · -0.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ZLAB +13.38 pp
ZLAB: +2.37% · LEGN: -11.01%
3M Horizon ZLAB +17.82 pp
ZLAB: -7.16% · LEGN: -24.98%
6M Horizon ZLAB +64.92 pp
ZLAB: +25.87% · LEGN: -39.05%
1Y Horizon ZLAB +56.22 pp
ZLAB: +9.25% · LEGN: -46.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs LEGN. Trailing 12-month operating profitability (ZLAB -63.0% vs LEGN 2.8%) and valuation multiples (ZLAB N/M vs LEGN 27.5x Forward P/E) are benchmarked directly in Pillar 4 below.

ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M
LEGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.36B
Gross Margin57.0%
Op. Margin2.8%
ROE / Fwd P/E-0.0% · 27.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LEGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.4%
IV Percentile 24th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LEGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published
LEGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6B market capitalization and 2.8% operating margin.
OpEx & R&D Reinvestment 54.2% of Rev ($736M)
90D Engineering Disclosures 0 Published

Investor FAQ ZLAB vs LEGN Key Questions & Quantitative Answers

As of Nov 16, 2026, Legend Biotech Corporation (LEGN) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.74 (N/M Forward P/E, -63.0% operating margin), whereas LEGN carries 42.8/100 (HOLD) at $16.45 (27.5x Forward P/E, 2.8% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. LEGN 42.8/100 HOLD), LEGN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (2.8% vs. -63.0% operating margin) and revenue trajectory (+32.0% vs. -6.8% YoY). Technical & Structure Timing Caution: ZLAB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 47.1); meanwhile LEGN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LEGN leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with LEGN at +32.0% YoY revenue growth and +0.0% YoY earnings growth on $1.36B TTM revenue (57.0% gross margin, 2.8% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus $1.36B for LEGN. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus 54.2% of Rev ($736M) (0 disclosures) for LEGN.

LEGN screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas LEGN trades at 27.5x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (3.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus LEGN (-0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, LEGN carries 42.4% implied volatility (24th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 82% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Legend Biotech Corporation American Depositary Shares (LEGN) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.